PVCT (PVCT) CEO converts 8% note into Series D-1 preferred stock

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-cash conversion of an 8% unsecured convertible promissory note into 47,180 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on February 20, 2026.

Each Series D-1 Preferred share is convertible into 10 common shares and will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation. Following this transaction, Pershing directly owned 2,660,987 Series D-1 Preferred shares.

Insider Trade Summary

47,180 shares exercised/converted

Mixed 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note	0	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock	47,180	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct); Series D-1 Convertible Preferred Stock — 2,660,987 shares (Direct)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On February 20, 2026, the 2025 Note was converted into 47,180 shares of Series D-1 Preferred Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	02/20/2026		M			$125,000	02/20/2025	02/20/2026	Series D-1 Convertible Preferred Stock(3)(4)	47,180	$0	$1,245,000	D
Series D-1 Convertible Preferred Stock	(1)	02/20/2026		M		47,180		02/20/2026	(2)	Common Stock	471,800	$0	2,660,987	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On February 20, 2026, the 2025 Note was converted into 47,180 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVCT CEO Edward Pershing report on this Form 4?

Edward Pershing reported a non-cash derivative conversion, where an 8% unsecured convertible promissory note was converted into 47,180 shares of Series D-1 Convertible Preferred Stock on February 20, 2026, rather than an open-market purchase or sale of Provectus Biopharmaceuticals common shares.

How many Series D-1 Preferred shares did Edward Pershing acquire in the PVCT filing?

Edward Pershing acquired 47,180 shares of Series D-1 Convertible Preferred Stock through the automatic conversion of an 8% unsecured convertible promissory note at a price of $2.862 per share, increasing his direct holdings of Series D-1 Preferred to a reported total of 2,660,987 shares after the transaction.

What are the key conversion terms of PVCT’s Series D-1 Convertible Preferred Stock?

Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 Preferred will automatically convert into common stock on December 31, 2028, unless it is converted earlier according to the terms of its certificate of designation.

What were the terms of the 8% unsecured convertible promissory note in the PVCT Form 4?

The 8% unsecured convertible promissory note, described as the 2025 Note, could be voluntarily converted into Series D-1 Convertible Preferred Stock at $2.862 per share while outstanding, and automatically converted into Series D-1 Preferred at the same $2.862 price twelve months after its issue date under the issuer’s 2025 Financing.

When did PVCT’s 2025 Note convert into Series D-1 Preferred Stock and in what amount?

On February 20, 2026, the 2025 Note automatically converted into 47,180 shares of Series D-1 Convertible Preferred Stock. This conversion followed the note’s terms, which provided for automatic conversion into Series D-1 Preferred at a price per share equal to $2.862 after twelve months.

How does the PVCT Form 4 describe Edward Pershing’s ownership after the conversion?

After the February 20, 2026 conversion, the Form 4 reports that Edward Pershing directly owned 2,660,987 shares of Series D-1 Convertible Preferred Stock. These holdings reflect his position in the preferred security, which itself is convertible into Provectus Biopharmaceuticals common shares under stated terms.